Axel Sjöblad
Chief Executive Officer.
Employed June 2019. Born 1967.
Axel Sjöblad has extensive experience in managing and developing global growth companies in medical technology and Life Science and was most recently CEO of BioGaia AB. He previously held CEO positions in Getinge Sverige AB and Gambro Lundia AB with responsibility for subsidiaries running operations in several European countries.
Education: M.Sc. in BA and Executive MBA.
Shareholding: 110 000 warrants.*
Marianne Olsson
VP Finance.
Employed 2016. Born 1961.
Marianne Olsson has 25 years of experience from Lund University where she has worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology. In addition, Marianne has been a member of the Board of the Faculty of Engineering LTH at Lund University, as well as a member of the management and Department Board at the Department of Immunotechnology.
Education: Accounting and executive management training at Lund University.
Shareholding: 114 285 shares and 15 000 warrants.*
Maria Agemark
VP Operations.
Employed 2015. Born 1974.
Maria Agemark has several years of experience from cell and molecular biology research. She has been with the company since its operational start with a responsibility for setting up and managing the laboratory operations. She has previously conducted postdoctoral research at the Department of Immunotechnology at Lund University.
Education: PhD in Biochemistry and BSc in Molecular Biology.
Shareholding: 75 000 shares and 15 000 warrants.*
Anna Chérouvrier Hansson
VP Business Development.
Employed 2017. Born 1973.
Anna has extensive experience from marketing, sales and business development from Camurus, Novo Nordisk, Gambro and DuPont among others. In addition, Anna has been a partner at Zitha Consulting, focusing on commercialisation strategy in the pharmaceutical industry and head of Life Science investments at Invest in Skåne.
Education: MSc in European Business Administration and Business Law, BSc in Business Administration.
Shareholding: 19 153 shares (privately and through related parties) and 25 000 warrants.*
Tina Dackemark Lawesson
VP Marketing and Communications.
Employed 2018. Born 1968.
Tina Dackemark Lawesson has long and broad experience from marketing, IR and communication at life science and technology companies in the build-up and growth phase. She has previously held similar positions at Invisio Communications, Cellavision and Enzymatica among others.
Education: Bachelor of Education (Languages) as well as studies in Journalism.
Shareholding: 15 000 warrants.*
Henrik Johansson
Chief Scientist.
Employed 2014. Born 1982.
Henrik Johansson has more than 10 years of experience of research and development within the fields of cell and molecular biology. He is specialized in in vitro assays for predictive immunotoxicology and is a co-developer of the GARD technology platform, which was first described in detail in his doctoral thesis.
Education: MSc. in Biotechnology Engineering, PhD in Immunotechnology.
Shareholding: 526 shares.*
Peter Nählstedt
VP Sales (acting).
Employed 2019. Born 1974.
Peter Nählstedt has 20 years of experience from international sales and marketing in leading positions in the life science and industrial sector. Previous experience includes structuring, building and leading globally successful commercial organisations at Probi, Trelleborg Marine Systems and GE Healthcare.
Education: MSc in Chemical Engineering, BSc in Business Administration.
Shareholding: 1 142 shares and 25 000 warrants.*
Mikael Wahlgren
Chief Legal Officer.
Employed 2016. Born 1965.
Mikael Wahlgren has previously worked as Group General Counsel for Alfa Laval Group as well as Corporate Counsel for several multinational companies. Since 2016, he runs a legal consultancy firm in which he acts as Legal Adviser, Arbitrator and Mediator.
Education: LLM.
Shareholding: 8 571 shares and 11 500 warrants through companies.*
* Last updated 31/12/2019.
